When people talk about the point of care diagnostics market, they tend to focus on North America and Europe — the big commercial markets, the sophisticated healthcare systems, the well-insured patients. And those markets are genuinely important. But the most transformative story in POC diagnostics right now isn't happening in Manhattan hospital emergency rooms or London GP surgeries. It's happening in rural sub-Saharan Africa, in remote South Asian villages, in underserved Latin American communities where centralised laboratory infrastructure is non-existent — and where POC testing is quite literally saving lives.

For low- and middle-income countries (LMICs), point of care testing isn't a convenience — it's a fundamental healthcare enabler. In settings where the nearest functioning lab is hours away, a rapid malaria test, an HIV viral load test, or a TB diagnostic that can be performed at the community health worker level without refrigeration or specialist training can be the difference between timely treatment and preventable death. Global health organisations including the WHO, GAVI, and the Gates Foundation have invested billions in POC diagnostic access initiatives, and commercial diagnostics companies are increasingly developing products specifically designed for LMIC deployment — simplified workflows, ambient temperature stability, low cost. This point of care testing market emerging economies and global access analysis examines the LMIC opportunity in depth and it's a genuinely compelling read for anyone interested in where the next phase of POC market growth is coming from.

The commercial model for LMIC POC diagnostics is also evolving in interesting ways. Tiered pricing — where the same product is sold at different price points in different markets — is becoming more common and more politically accepted. Cross-subsidisation models, where profits from high-income markets fund subsidised access in LMICs, are being operationalised by several major diagnostics companies. And social enterprise models, where purpose-driven companies build LMIC-focused businesses with hybrid commercial and philanthropic funding, are demonstrating that you can build a sustainable business while genuinely expanding access to life-saving diagnostics.

The point of care diagnostics global access market is ultimately a story about what happens when good technology, the right business models, and genuine political will align around a shared health objective. The opportunity is enormous — both commercially and in terms of human impact — and the companies that figure out how to navigate it successfully will be among the most consequential actors in global health over the next decade.